Acadia Pharma ACAD

HealthcareMarket cap $4B1 connection

Acadia makes Nuplazid - the first and only FDA-approved drug for Parkinson's disease psychosis. It's expanding into Alzheimer's psychosis and Rett syndrome. CNS (central nervous system) diseases are notoriously difficult to treat but Acadia has found a niche where it faces essentially no competition.

Explore Acadia Pharma on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

BiogenHealthcare · $35BCompeting CNS neurology drug portfolios

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Acadia Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=ACAD" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Acadia Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.